|Bid||44.15 x 100|
|Ask||46.00 x 200|
|Day's Range||45.03 - 46.97|
|52 Week Range||26.26 - 63.73|
|PE Ratio (TTM)||-19.31|
|Earnings Date||Oct 25, 2017 - Oct 30, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||65.93|
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
About 77.2% of analysts tracking BioMarin Pharmaceuticals in September 2017 suggested some form of a “buy” rating.
Things have been looking better since January.